Tests sacituzumab tirumotecan with pembrolizumab in endometrial cancer
Tests sacituzumab tirumotecan plus pembrolizumab in adults with advanced endometrial cancer.
Plain-language title generated from the registry record
Registry title: A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Key facts
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linhai, Linyi, Liuzhou, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Yibin, Zhanjiang, and Zhengzhou, ChinaSee the 33 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with advanced or recurrent endometrial cancer whose cancer cells are mismatch repair proficient (pMMR). It compares sac-TMT with pembrolizumab against pembrolizumab alone.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Primary advanced or recurrent endometrial carcinoma, confirmed as pMMR. Measurable Stage III, or measurable or non-measurable Stage IV or recurrent disease.
- Earlier treatment
- No earlier systemic therapy for endometrial cancer, with set exceptions: 1 earlier line of platinum-based chemotherapy given before or after surgery with the aim of removing all the disease, earlier radiation, or earlier hormonal therapy stopped at least 1 week before.
- Biomarker or test result
- The cancer must be proficient mismatch repair (pMMR).
Main reasons for not taking part
- Carcinosarcoma, neuroendocrine tumors or endometrial sarcoma
- Cancer that is mismatch repair deficient (dMMR)
- Can have surgery that removes all tumor, or radiotherapy meant to remove all the disease
- Severe dry eye, severe eyelid gland disease or severe corneal disease
- Earlier treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs, TROP2-targeted antibody drug conjugates, or topoisomerase I inhibitor antibody drug conjugates
Read by machine on 12 November 2026.
Where in China
- Peking University Peoples Hospital (Site 0845)Beijing, ChinaContact: Study CoordinatorTaking people
- The First Hospital Of Jilin University (Site 0815)Changchun, ChinaContact: Study CoordinatorTaking people
- Hunan Cancer Hospital (Site 0826)Changsha, ChinaContact: Study CoordinatorTaking people
- Xiangya Hospital Central South University (Site 0821)Changsha, ChinaContact: Study CoordinatorTaking people
- West China Second University Hospital, Sichuan University (Site 0849)Chengdu, ChinaContact: Study CoordinatorTaking people
- Chongqing University Cancer Hospital (Site 0838)Chongqing, ChinaContact: Study CoordinatorTaking people
- Fujian Province Cancer Hospital (Site 0802)Fuzhou, ChinaContact: Study CoordinatorTaking people
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University (Site 0801)Guangzhou, ChinaContact: Study CoordinatorTaking people
- Sun Yat-sen University Cancer Center (Site 0846)Guangzhou, ChinaContact: Study CoordinatorTaking people
- Zhujiang Hospital of Southern Medical University (Site 0829)Guangzhou, ChinaContact: Study CoordinatorTaking people
- The Affiliated Women's Hospital of Zhejiang University (Site 0834)Hangzhou, ChinaContact: Study CoordinatorTaking people
- Harbin Medical University Cancer Hospital (Site 0850)Harbin, ChinaContact: Study CoordinatorTaking people
- Anhui Provincial Hospital (Site 0830)Hefei, ChinaContact: Study CoordinatorTaking people
- Shandong Cancer Hospital (Site 0803)Jinan, ChinaContact: Study CoordinatorTaking people
- Yunnan Province Cancer Hospital (Site 0811)Kunming, ChinaContact: Study CoordinatorTaking people
- Taizhou Hospital of Zhejiang Province (Site 0809)Linhai, ChinaContact: Study CoordinatorTaking people
- LinYi Cancer Hospital (Site 0820)Linyi, ChinaContact: Study CoordinatorTaking people
- Liuzhou People's Hospital (Site 0831)Liuzhou, ChinaContact: Study CoordinatorTaking people
- Jiangxi Maternal and Child Health Hospital (Site 0807)Nanchang, ChinaContact: Study CoordinatorTaking people
- Nanjing First Hospital (Site 0828)Nanjing, ChinaContact: Study CoordinatorTaking people
- Guangxi Medical University Affiliated Tumor Hospital. (Site 0825)Nanning, ChinaContact: Study CoordinatorTaking people
- Obstetrics & Gynecology Hospital of Fudan University (Site 0818)Shanghai, ChinaContact: Study CoordinatorTaking people
- Shanghai Tenth People's Hospital (Site 0847)Shanghai, ChinaContact: Study CoordinatorTaking people
- Cancer Hospital of Shantou University Medical College (Site 0827)Shantou, ChinaContact: Study CoordinatorTaking people
- Shanxi Provincial Cancer Hospital (Site 0843)Taiyuan, ChinaContact: Study CoordinatorTaking people
- The First Affiliated Hospital of Wenzhou Medical University (Site 0805)Wenzhou, ChinaContact: Study CoordinatorTaking people
- Wuhan Union Hospital Cancer Center (Site 0824)Wuhan, ChinaContact: Study CoordinatorTaking people
- The First Affiliated Hospital of Xi'an Jiaotong University (Site 0816)Xi'an, ChinaContact: Study CoordinatorTaking people
- The First Affiliated hospital of Xiamen University (Site 0822)Xiamen, ChinaContact: Study CoordinatorTaking people
- The Second People's Hospital of Yibin (Site 0840)Yibin, ChinaContact: Study CoordinatorTaking people
- Affiliated Hospital of Guangdong Medical University (Site 0823)Zhanjiang, ChinaContact: Study CoordinatorTaking people
- Henan Cancer Hospital (Site 0806)Zhengzhou, ChinaContact: Study CoordinatorTaking people
- The Second Affiliated Hospital of Zhengzhou University (Site 0833)Zhengzhou, ChinaContact: Study CoordinatorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT06952504EU 2024-519331-42-00
- Record updated
- 10 November 2026
- Original description
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.Read full original descriptionShow less
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.
* EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery
Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells.
The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
Inclusion: Has a histologically confirmed diagnosis of primary advanced or recurrent endometrial carcinoma that has been confirmed as proficient mismatch repair (pMMR); Has radiographically evaluable disease, with measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), as assessed by the investigator; Has received no prior systemic therapy for endometrial carcinoma except the following conditions as pre-specified by the protocol: 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent, prior radiation with or without radiosensitizing chemotherapy if >2 weeks before the start of induction treatment, or prior hormonal therapy for treatment of endometrial carcinoma that was discontinued ≥1 week before the start of induction treatment.
Exclusion: Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease; Received prior therapy in any setting with any of the following: anti-programmed cell death 1 protein, anti-programmed cell death ligand 1, anti-programmed cell death ligand 2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor; trophoblast cell surface antigen 2-targeted antibody drug conjugate; or topoisomerase I inhibitor-containing antibody drug conjugate; Is a candidate for debulking surgery resulting in complete removal of all tumor and no evidence of radiological disease following surgery, or curative-intent radiotherapy at the time of enrollment; Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing; Has uncontrolled, significant cardiovascular disease or cerebrovascular disease; Human Immunodeficiency Virus-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease; Has carcinosarcoma, neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of sarcomas; Has endometrial carcinoma of any histology that is mismatch repair deficient (dMMR).